title: Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism.
abstract: OBJECTIVE
  To determine whether an increased dosage of esomeprazole 40 mg twice daily in triple therapy improved the Helicobacter pylori eradication rate for patients with different genotypes of S-mephenytoin 4'-hydroxylase (CYP2C19).
  
  
  METHODS
  Two hundred H. pylori-infected dyspeptic patients were randomized to receive clarithromycin 500 mg twice daily and amoxicillin 1 g twice daily plus either omeprazole 20 mg or esomeprazole 40 mg twice daily for 1 week. Six weeks later, the success of H. pylori eradication was defined. The genotyping of CYP2C19 in each patient was defined as homologous, heterologous extensive metabolizer or poor metabolizer.
  
  
  RESULTS
  The age, gender, drug compliance and proportion of CYP2C19 genotypes were similar between the two groups. The H. pylori eradication rates were also similar between the omeprazole group and the esomeprazole group (intention-to-treat analysis: 79% vs. 86%, P > 0.05; per-protocol analysis: 85% vs. 94%, P > 0.05). For patients classified as homologous extensive metabolizers, the per-protocol H. pylori eradication rate was significantly higher in the esomeprazole group than in the omeprazole group (93% vs. 76%, P < 0.05).
  
  
  CONCLUSIONS
  Esomeprazole 40 mg twice daily for triple therapy may improve the H. pylori eradication compared to omeprazole-based therapy, but only for homologous extensive metabolizers of CYP2C19.
authors.affiliation: Department of Internal Medicine, Medical College, National Cheng Kung University, Tainan, Taiwan. sheubs@mail.ncku.edu.tw
authors.forename: B-S
authors.initials: BS
authors.lastname: Sheu
authors.forename: A-W
authors.initials: AW
authors.lastname: Kao
authors.forename: H-C
authors.initials: HC
authors.lastname: Cheng
authors.forename: S-F
authors.initials: SF
authors.lastname: Hunag
authors.forename: T-W
authors.initials: TW
authors.lastname: Chen
authors.forename: C-C
authors.initials: CC
authors.lastname: Lu
authors.forename: J-J
authors.initials: JJ
authors.lastname: Wu
mesh_terms: D000328:Adult; D000658:Amoxicillin / Q000008:administration & dosage / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics / Q000378:metabolism*; D016009:Chi-Square Distribution; D017291:Clarithromycin / Q000008:administration & dosage / Q000627:therapeutic use; D065731:Cytochrome P-450 CYP2C19; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D064098:Esomeprazole; D005260:Female; D005500:Follow-Up Studies; D005753:Gastric Mucosa / Q000201:enzymology*; D005838:Genotype; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000201:enzymology; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D006899:Mixed Function Oxygenases / Q000235:genetics / Q000378:metabolism*; D009853:Omeprazole / Q000008:administration & dosage* / Q000627:therapeutic use; D012306:Risk
chemical_list: D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D000658:Amoxicillin; D006899:Mixed Function Oxygenases; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D017291:Clarithromycin; D009853:Omeprazole; D064098:Esomeprazole